RAPT Therapeutics Inc announces that researchers presented encouraging results from preclinical and healthy volunteer studies for RPT193 at the Society for Investigative Dermatology (SID) Meeting. RPT193 is a small molecule, once-daily oral therapy in development for the treatment of atopic dermatitis and other allergic inflammatory diseases.

During the session, Laurence Cheng, MD, PhD, Senior Medical Director at RAPT Therapeutics, presented blinded Phase 1a data from healthy volunteer cohorts of an ongoing seamless Phase 1 study showing that once-daily oral dosing of RPT193 for seven days achieved target drug levels and target coverage with an excellent safety profile in healthy volunteers. In addition, Dr Cheng noted that in multiple preclinical studies of allergic skin inflammation, once-daily dosing of RPT193 demonstrated efficacy and reduction of Th2 cytokines comparable to treatment with currently available biologics that work by blocking interleukin-4 (IL-4) and IL-13, the major drivers of allergic inflammatory disease.